Sidley represented the underwriters in the US$129.4 million initial public offering by Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying translational bioinformatics to every stage of the drug development process. Morgan Stanley, Jefferies, Cowen, and Guggenheim Securities acted as joint book-running managers of the offering. Continue reading

See all Member News